GSK plc: EPS $1.47 vs $1.33 expected; revenue $11.8B vs $11.7B
Key Facts
Q3 FY2026 results
| Metric | Actual | Estimate | Surprise | Year ago |
|---|---|---|---|---|
| EPS (USD) | 1.47 | 1.33 | +10.5% | 1.48 |
| Revenue (USD bn) | 11.82 | 11.74 | +0.7% | 11.32 |
Recent reports: actual vs estimate
| Reported | Period | EPS (USD) | Estimate | Surprise | Revenue (USD bn) | Estimate | Surprise |
|---|---|---|---|---|---|---|---|
| Oct 28, 2026 | Q3 FY2026 | 1.47 | 1.33 | +10.5% | 11.82 | 11.74 | +0.7% |
| Jul 28, 2026 | Q2 FY2026 | 1.36 | 1.27 | +7.1% | 11.18 | 11.02 | +1.4% |
| Apr 29, 2026 | Q1 FY2026 | 1.24 | 1.16 | +6.9% | 10.30 | 10.23 | +0.7% |
| Feb 4, 2026 | Q4 FY2025 | 0.68 | 0.64 | +6.3% | 11.78 | 11.41 | +3.2% |
| Oct 29, 2025 | Q3 FY2025 | 1.48 | 1.26 | +17.5% | 11.32 | 11.04 | +2.6% |
| Jul 30, 2025 | Q2 FY2025 | 1.23 | 1.12 | +9.8% | 10.61 | 10.50 | +1.1% |
| Apr 30, 2025 | Q1 FY2025 | 1.13 | 1.08 | +4.6% | 10.04 | 9.72 | +3.3% |
| Feb 5, 2025 | Q4 FY2024 | 0.59 | 0.44 | +34.1% | 10.16 | 9.54 | +6.5% |
Source: Figures from the EL7 database. Estimates are the analyst consensus carried by our data vendor (FMP), not official figures. Figures are in USD as carried for this US-traded line; the company reports in another currency.
GSK plc results: EPS $1.47 vs $1.33 expected; revenue $11.8B vs $11.7B. The results cover the company's Q3 FY2026. EPS came in above analysts' estimate by 10.5%; revenue above the estimate by 0.7%. Figures are in USD as carried for this US-traded line; the company reports in GBP.
Revenue was up 4.4% from $11.3 billion a year earlier (Q3 FY2025). EPS was down 0.7% from $1.48 a year earlier. On its record, EPS topped analysts' estimates in 7 of 7 earlier comparable reports.
What the results mean
GSK plc operates across vaccines, specialty medicines and general medicines. Understanding its results requires attention to the sales mix across these areas, because demand for prevention differs in character from demand for chronic disease treatments.
The company's business drivers span infectious disease vaccines and treatments for human immunodeficiency virus, oncology, respiratory conditions and immunology. This breadth diversifies revenue sources, while the contribution of different products to profitability remains important to understanding operating performance.
Research and development and research partnerships underpin the renewal of the company's portfolio. Their commercial importance lies in translating innovation into marketable medicines and vaccines while managing the spending associated with their development.
What to watch on the earnings call: Watch management's discussion of demand for vaccines and specialty medicines and how the product mix affects margins. Research spending priorities, the role of partnerships in portfolio development and the commercial business's capacity to support that spending also merit attention.
For the full analysis of GSK plc stock — valuation, scores and financial statements — see the stock page linked with this story.